{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T22:22:25Z","timestamp":1791152545581,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1016\/j.jhep.2004.11.018","type":"journal-article","created":{"date-parts":[[2004,12,15]],"date-time":"2004-12-15T21:44:13Z","timestamp":1103147053000},"page":"323-328","source":"Crossref","is-referenced-by-count":72,"title":["Barriers to interferon-\u03b1 therapy are higher in intravenous drug users than in other patients with acute hepatitis C"],"prefix":"10.1016","volume":"42","author":[{"given":"Barbara","family":"Broers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beat","family":"Helbling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Fran\u00e7ois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Chuard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Hadengue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Negro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2004.11.018_bib1","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJM199608293350904","article-title":"Hepatitis C virus-associated fulminant hepatic failure","volume":"335","author":"Farci","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2004.11.018_bib2","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/0016-5085(94)90130-9","article-title":"Effects of interferon beta on non-A, non-B acute hepatitis: a prospective, randomized, controlled-dose study Japan Acute Hepatitis Cooperative Study Group","volume":"107","author":"Takano","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2004.11.018_bib3","doi-asserted-by":"crossref","unstructured":"National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C: 2002, June 10\u201312. Hepatology 2002;36:S3\u2013S20.","DOI":"10.1002\/hep.1840360703"},{"key":"10.1016\/j.jhep.2004.11.018_bib4","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1136\/gut.52.12.1784","article-title":"Treatment of hepatitis C. The 2002 French consensus","volume":"52","author":"Dhumeaux","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2004.11.018_bib5","doi-asserted-by":"crossref","first-page":"S195","DOI":"10.1002\/hep.1840360725","article-title":"Therapy of acute hepatitis C","volume":"36","author":"Alberti","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2004.11.018_bib6","first-page":"CD000369","article-title":"Interferon for acute hepatitis C (Cochrane Review)","author":"Poynard","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jhep.2004.11.018_bib7","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1056\/NEJMoa011232","article-title":"German Acute Hepatitis C Therapy Group. Treatment of acute hepatitis C with interferon alfa-2b","volume":"345","author":"Jaeckel","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2004.11.018_bib8","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0016-5085(03)00668-1","article-title":"Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance","volume":"125","author":"Gerlach","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2004.11.018_bib9","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1053\/jhep.2003.50019","article-title":"Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load","volume":"37","author":"Hofer","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2004.11.018_bib10","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/hep.20196","article-title":"Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial","volume":"39","author":"Nomura","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2004.11.018_bib11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2036.2004.02023.x","article-title":"The Belgian Association for the Study of the Liver (BASL). Treatment of acute hepatitis C with interferon alpha-2b: early initiation of treatment is the most effective predictive factor of sustained viral response","volume":"20","author":"Delwaide","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2004.11.018_bib12","first-page":"877","article-title":"H\u00e9patite C en Suisse","volume":"46","year":"2001","journal-title":"Bull OFSP"},{"key":"10.1016\/j.jhep.2004.11.018_bib13","doi-asserted-by":"crossref","unstructured":"EASL International Consensus Conference on hepatitis C: Paris, 26\u201327 February 1999. Consensus statement. J Hepatol 1999;31:3\u20138.","DOI":"10.1016\/S0168-8278(99)80367-5"},{"key":"10.1016\/j.jhep.2004.11.018_bib14","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/S0002-9270(03)00708-1","article-title":"Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse","volume":"98","author":"Van Thiel","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2004.11.018_bib15","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/jhep.2003.50031","article-title":"Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups","volume":"37","author":"Schaefer","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2004.11.018_bib16","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0149-2918(02)80065-0","article-title":"Controlled clinical trial to assess the response of recent heroin abusers with chronic hepatitis C virus infection to treatment with interferon alpha-n2b","volume":"24","author":"Neri","year":"2002","journal-title":"Clin Ther"},{"key":"10.1016\/j.jhep.2004.11.018_bib17","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/0002-9343(92)90166-9","article-title":"Human immunodeficiency virus infection in intravenous drug users: a model for primary care","volume":"93","author":"O'Connor","year":"1992","journal-title":"Am J Med"},{"key":"10.1016\/j.jhep.2004.11.018_bib18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF02599388","article-title":"Differences in access to zidovudine (AZT) among symptomatic HIV-infected persons","volume":"6","author":"Stein","year":"1991","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.jhep.2004.11.018_bib19","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1081\/JA-100104091","article-title":"Drug use and barriers to use of health care services","volume":"36","author":"McCoy","year":"2001","journal-title":"Subst Use Misuse"},{"key":"10.1016\/j.jhep.2004.11.018_bib20","first-page":"327","article-title":"Mutual mistrust in the medical care of drug users: the keys to the \u2018narc\u2019 cabinet","volume":"17","author":"Merrill","year":"2002","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.jhep.2004.11.018_bib21","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1001\/jama.280.6.547","article-title":"Barriers to use of free antiretroviral therapy in injection drug users","volume":"280","author":"Strathdee","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2004.11.018_bib22","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1056\/NEJM199408183310707","article-title":"Medical care for injection-drug users with human immunodeficiency virus infection","volume":"331","author":"O'Connor","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2004.11.018_bib23","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-129-7-199810010-00012","article-title":"Rethinking nonadherence: historical perspectives on triple-drug therapy for HIV disease","volume":"129","author":"Lerner","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2004.11.018_bib24","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s11606-002-0044-3","article-title":"Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users","volume":"17","author":"Arnsten","year":"2002","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.jhep.2004.11.018_bib25","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jama.285.8.1003","article-title":"Former addicts face barriers to treatment for HCV","volume":"285","author":"Stephenson","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2004.11.018_bib26","first-page":"010802","article-title":"The access of injecting drug users to hepatitis C treatment is low and should be improved","volume":"5","author":"Wiessing","year":"2001","journal-title":"Eurosurveillance Weekly"},{"key":"10.1016\/j.jhep.2004.11.018_bib27","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0399-8320(04)95008-7","article-title":"Management of hepatitis C in active drugs users: experience of an addiction care hepatology unit","volume":"28","author":"Cournot","year":"2004","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.jhep.2004.11.018_bib28","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJM200107193450312","article-title":"Treatment of chronic hepatitis C in active drug users","volume":"345","author":"Davis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2004.11.018_bib29","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJM200107193450311","article-title":"Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?","volume":"345","author":"Edlin","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2004.11.018_bib30","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/j.1360-0443.2004.00821.x","article-title":"Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules?","volume":"99","author":"Schaefer","year":"2004","journal-title":"Addiction"},{"key":"10.1016\/j.jhep.2004.11.018_bib31","first-page":"1091","article-title":"Hepatitis C virus screening in drug users in an addiction out-patient unit","volume":"26","author":"Grando-Lemaire","year":"2002","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.jhep.2004.11.018_bib32","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/hep.20279","article-title":"A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance","volume":"40","author":"Mauss","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2004.11.018_bib33","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0376-8716(02)00010-8","article-title":"Treating hepatitis C in methadone maintenance patients: an interim analysis","volume":"67","author":"Sylvestre","year":"2002","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jhep.2004.11.018_bib34","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000049487","article-title":"Treatment of chronic hepatitis C in injecting drug users: 5 years\u2019 follow-up","volume":"8","author":"Dalgard","year":"2002","journal-title":"Eur Addict Res"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827804005392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827804005392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T09:23:02Z","timestamp":1548926582000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827804005392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["S0168827804005392"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2004.11.018","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2005,3]]}}}